Neoplasms

All Conditions

Symptoms and General Pathology

Digestive System Diseases

Rare Diseases

Carcinoma

Recurrence

Cholangiocarcinoma

Gallbladder Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Biliary Tract Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Biliary Tract Diseases

Gastrointestinal Diseases

Gallbladder Diseases

Bile Duct Cancer

Gallbladder Cancer

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Trastuzumab

Cetuximab

Everolimus

Oxaliplatin

Crizotinib

Lapatinib

Sorafenib

Gefitinib

The patients wil receive conventional chemotherapy(FORFIRINOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.

The patients wil receive conventional chemotherapy(FORFIRINOX)

Drug: FORFIRINOX Conventional chemotherapy:gemcitabine and oxaliplatin Drug: Cetuximab Drug: Trastuzumab Drug: Gefitinib Drug: Lapatinib Drug: Everolimus Drug: Sorafenib Drug: Crizotinib

conventional chemotherapy(FORFIRINOX) combined with target agents

conventional chemotherapy(FORFIRINOX)

yingbin liu, PHD

Yingbin Liu, PHD

The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with FORFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect genetic changes or abnormalities. immuno-histochemistry tests reveal the abnormal activation status of signal pathways involved in study.These information will be used to recommend target therapy which may be more likely to result in a beneficial response.Patients will receive target anti-tumor agents according to the result of genomic and proteomic profiling.

Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year. The progression is defined consistent with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria for solid tumors.

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Ruijin Hospital

RenJi Hospital

Eastern Hepatobiliary Surgery Hospital

Huashan Hospital

Shanghai Jiao Tong University School of Medicine

head of general surgery department，xin hua Hospital Affiliation: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma	NCT03768375	Cholangiocarcin... Gallbladder Can...	conventional ch... conventional ch...	18 Years - 80 Years	Shanghai Jiao Tong University School of Medicine
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma	NCT03768375	Cholangiocarcin... Gallbladder Can...	conventional ch... conventional ch...	18 Years - 80 Years	Shanghai Jiao Tong University School of Medicine
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma	NCT03768375	Cholangiocarcin... Gallbladder Can...	conventional ch... conventional ch...	18 Years - 80 Years	Shanghai Jiao Tong University School of Medicine

Spots Global Cancer Trial Database for conventional chemotherapy(forfirinox) combined with target agents